Conoscenze

RBD sequence

Mechanism of action of an adjuvanted protein vaccine based on the RBD from SARS-CoV-2 Spike protein

Antibody and B-cell responses to PHH-1V81 XBB.1.16-adapted SARS-CoV-2 booster vaccination are associated with variant neutralization

Safety and Immunogenicity of PHH-1V Booster Against SARS-CoV-2 Variants, Including Omicron Subvariants: Results from a Phase IIb Open-Label Extension Study

ethinking optimal immunogens to face SARS-CoV-2. Evolution through vaccination

Rethinking optimal immunogens to face SARS-CoV-2. Evolution through vaccination

Antibody and B-cell responses to PHH-1V81 XBB.1.16-adapted SARS-CoV-2 booster vaccination are associated with variant neutralization

Antibody and B-cell responses to PHH-1V81 XBB.1.16-adapted SARS-CoV-2 booster vaccination are associated with variant neutralization

Immunogenicity and safety of PHH-1V COVID-19 vaccine as a heterologus booster in adolescents

Immunogenicity and safety of PHH-1V COVID-19 vaccine as a heterologus booster in adolescents

Correlates of Protection for COVID-19 Vaccines

34th ECCMID Integrated Symposium, 2024: COVID-19 booster immunization

knowledge

Humoral and cellular immune responses after 6 months of a heterologous SARS-CoV-2 booster with the protein-based PHH-1V vaccine in a phase IIb trial

knowledge

Safety and immunogenicity of the protein-based PHH-1V compared to BNT162b2 as a heterologous SARS-CoV-2 booster vaccine in adults vaccinated against COVID-19

knowledge

Preclinical evaluation of PHH-1V candidate against SARS-CoV-2 in non-human primates